Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- Kenporen Proposes Higher Copays for Choosing Costlier Drugs
September 26, 2025
- Japan Wholesalers’ Profit Margin Improves to 1.11% in FY2024
September 26, 2025
- JPMA Think Tank Chief Pledges to Back Policy Debates with Evidence
September 26, 2025
- Japanese Pharma-Cosmetic Union Breaks from UA Zensen, Set to Join Rengo
September 25, 2025
- JPMA to Overhaul Guideline for Handling Drug Inquiries This Fall: Consultation Chair
September 25, 2025
- Generic Use Rate at 89.6% in April: Payer
September 25, 2025
- JPMA Publishes TPP Overview to Bridge Academia and Industry: R&D Chair
September 22, 2025
- JPMA Sets Up Multilateral Advocacy Group to Bolster Global Voice: International Affairs Chair
September 19, 2025
- JPMA Launches Task Force on AI and Open Innovation Challenges: IP Chief
September 18, 2025
- JPMA to Broaden Base of Biopharma Talent through On-Site Training: Committee Chair
September 17, 2025
- JPMA to Compile Best Practices on Patient and Public Involvement
September 16, 2025
- JPMA Names Ex-MHLW Pharma Official Yoshida as Senior Managing Director
September 12, 2025
- JPMA Plans Joint Training with HCPs to Improve Promo Materials: Review Board Chair
September 11, 2025
- JPMA to Step Up Public Outreach, Build Understanding of Pharma, Says PR Head
September 10, 2025
- JPMA Quality Committee Launches Task Force on DX in Commercial Production
September 9, 2025
- JPMA Code & Compliance Chair Stresses Need to Embed Spirit of Revised COP
September 8, 2025
- JPMA ICH Project Chair Sees RWE as Potential Complement to Clinical Trials
September 5, 2025
- Rules for Measuring Industry-Wide Emissions in the Works: JPMA Environment Chief
September 4, 2025
- JPMA Exec Calls for Expansion of Pull Incentives for Infectious Disease Drugs
September 4, 2025
- JPMA Regulatory Chief Seeks Balanced Approach on Japanese PI Waivers
September 3, 2025
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…